Observational studySleep & breathing = Schlaf & Atmung2026
Serum asprosin levels in obstructive sleep apnea syndrome: relationship with disease severity and adipose tissue distribution.
Observational study in Sleep & breathing = Schlaf & Atmung, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Association Between Sleep Disorders and Adverse Cardiovascular Outcomes in Patients with Chronic Obstructive Pulmonary Disease: Insights from the UK Biobank.International journal of chronic obstructive pulmonary disease · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundObstructive sleep apnea syndrome (OSAS) is a common disease with systemic effects associated with inflammation and metabolic disorders. In recent years, asprosin, an adipokine secreted from adipose tissue and involved in energy balance and insulin resistance, has attracted attention in relation to metabolic diseases. This study aimed to evaluate whether asprosin is a potential biomarker by examining the relationship between serum asprosin levels and disease severity and body fat tissue distribution in OSAS patients.
methodsThis prospective, single-center, cross-sectional observational study was conducted between January 2024 and January 2025 at Atatürk University Faculty of Medicine Sleep Laboratory. Patients presenting with symptoms suggestive of OSAS and undergoing polysomnography (PSG) were included in the study. Participants were grouped according to the apnea-hypopnea index (AHI). In order to minimize potential confounding factors, individuals with diabetes, malignancy, chronic organ diseases, or recent use of drugs or antioxidant supplements affecting metabolism were excluded. Serum asprosin levels were measured using the ELISA. Skinfold thickness measurements evaluated subcutaneous adipose tissue distribution. Statistical analyses were performed with SPSS version 25.0 software.
resultsThe overall mean age of the participants was 47.2 ± 12.6 years, and 58.7% were male (n = 71). Serum asprosin levels were significantly higher in OSAS patients than in the control group (p < 0.001). As the disease severity increased, serum asprosin levels also increased. In addition, a positive correlation was found between serum asprosin levels and AHI, neck circumference, subscapular, abdominal, and thigh skinfolds (R = 0.896, 0.726, 0.582, 0.677, 0.671; p < 0.001, respectively). As a result of ROC analysis, a cut-off value of 22.49 ng/mL was determined for serum asprosin level in distinguishing the severe OSAS group. At this threshold value, sensitivity was calculated as 82%, specificity as 97%, and area under the curve (AUC) as 0.886.
conclusionThis study observed that serum asprosin levels were higher in OSAS patients than in the control group and increased with disease severity. In addition, asprosin levels were determined to be related to body fat tissue distribution. These findings suggest that asprosin can be used as a potential biomarker in diagnosing OSAS and assessing disease severity.
Indexed as
Identifiers
41493705What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.